Drug Trial Radar · NCT05400369
A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Last checked: Nov 20, 2026Latest source record: Jan 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
140
Actual
Start
Aug 10, 2022
Primary completion
Sep 25, 2024
Study completion Sep 25, 2024
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- First posted
- Jun 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease, that causes obstructed airflow from the lungs that causes persistent obstructive airflow limitation. Acute exacerbation, especially frequent exacerbation, is associated with an increased risk of death in COPD patients. The most common causes of acute attacks are viral and bacterial infections. This study will assess the efficacy and safety of sitafloxacin, a quinolone antibacterial drug, in participants with AECOPD.
Conditions
- COPD Exacerbation Acute
Interventions
SitafloxacinDrug
Oral administration, 50 mg tablets
Moxifloxacin HydrochlorideDrug
Oral administration, 400 mg tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Achieving Clinical Efficacy in Participants With Acute Exacerbation of Chronic Obstructive Pulmonary DiseaseTime frame: End of treatment (approximately Day 10 post-dose)
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Peking University Shougang Hospital
Beijing, China
The Third Xiangya Hospital of Central South University
Changsha, China
The Sixth People's Hospital of Chengdu
Chengdu, China
West China Hospital Sichuan University
Chengdu, China
The First Affiliated Hospital of Dalian Medical University
Dalian, China
Fuyang People's Hospital
Fuyang, China
Nanfang Hospital Southern Medical University
Guangzhou, China
Qilu Hospital of Shandong University
Jinan, China
Gaozhou People's Hospital
Maoming, China
Huadong Hospital Affiliated To Fudan University
Shanghai, China
Shenzhen People's Hospital
Shenzhen, China
Tianjin Medical University General Hospital
Tianjin, China
The Sixth Hospital of Wuhan
Wuhan, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, China
The First Affiliated Hospital of Hebei North University
Zhangjiakou, China
Affiliated Hospital of Guangdong Medical University
Zhanjiang, China
Henan Provincial People's Hospital
Zhengzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.